At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 448 enrolled
Drug / intervention
vadadustat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
The University of Texas Health Science Center, Houston·interventional·Posted Jul 20, 2020·Updated Mar 26, 2025
In Brief
A Phase 2 clinical trial evaluating vadadustat and placebo for Acute Respiratory Distress Syndrome and Coronavirus Infection. Completed, enrolled 448 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAkebia Therapeutics, United States Department of Defense
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartAug 2020
Primary CompletionMar 2022
Study CompletionMar 2022
TodayJul 2026
First PostedJul 20, 2020
Enrollment StartAug 22, 2020
Primary CompletionMar 7, 2022
Study CompletionMar 25, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.0 years ago
Interventions
vadadustatdrug
Participants will receive vadadustat once daily for 14 days.
placebodrug
Participants will receive matching placebo once daily for 14 days.